Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,972,984
  • Shares Outstanding, K 599,700
  • Annual Sales, $ 23,747 M
  • Annual Income, $ 8,394 M
  • 60-Month Beta 1.11
  • Price/Sales 5.27
  • Price/Cash Flow 10.74
  • Price/Book 10.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 3.47
  • Number of Estimates 9
  • High Estimate 3.56
  • Low Estimate 3.31
  • Prior Year 3.69
  • Growth Rate Est. (year over year) -5.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
193.51 +1.66%
on 09/16/19
210.97 -6.75%
on 08/30/19
-7.30 (-3.58%)
since 08/16/19
3-Month
173.12 +13.63%
on 07/26/19
211.90 -7.16%
on 08/13/19
+18.33 (+10.28%)
since 06/17/19
52-Week
166.30 +18.29%
on 05/15/19
211.90 -7.16%
on 08/13/19
-4.09 (-2.04%)
since 09/17/18

Most Recent Stories

More News
Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019

Amgen (NASDAQ:AMGN) today announced that new data from its oncology pipeline and marketed product portfolio will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona,...

AMGN : 196.72 (+1.36%)
Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

MRK : 82.51 (+0.59%)
SGEN : 71.95 (+1.18%)
NCNA : 7.61 (-9.24%)
AMGN : 196.72 (+1.36%)
The Zacks Analyst Blog Highlights: Amgen, Tokyo Electron and Kinross Gold

The Zacks Analyst Blog Highlights: Amgen, Tokyo Electron and Kinross Gold

TOELY : 48.3400 (+0.25%)
KGC : 5.18 (+5.28%)
AMGN : 196.72 (+1.36%)
Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck

Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.

ALDR : 18.70 (+1.08%)
LLY : 111.12 (+0.90%)
NVS : 86.53 (+0.45%)
AMGN : 196.72 (+1.36%)
Adaptive Biotechnologies Enters Partnership for Use Of clonoSEQ(R) as Preferred MRD Test for Drug Development Across Amgen's Hematology Franchise

Adaptive Biotechnologies Corporation (Nasdaq:ADPT) today announced it has entered into a global agreement with Amgen for the use of Adaptive's next-generation sequencing (NGS)-based clonoSEQAssay to assess...

ADPT : 40.35 (-2.84%)
AMGN : 196.72 (+1.36%)
Top Stock Picks for Week of September 16, 2019

A Biotech Pioneer and an E-Commerce Giant.

BABA : 179.00 (+1.09%)
AMGN : 196.72 (+1.36%)
Aimmune's Peanut Allergy Drug Gets FDA Committee's Support

Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.

AIMT : 22.38 (-3.62%)
REGN : 288.12 (+0.78%)
AMGN : 196.72 (+1.36%)
SNY : 44.30 (+1.61%)
S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels

S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q2 2019 S&P 500® stock buybacks, or share repurchases, were $164.5 billion. This was the second consecutive quarterly decline after four...

GOOGL : 1,229.88 (-0.14%)
AAPL : 220.70 (+0.36%)
CSCO : 49.41 (-1.10%)
C : 69.48 (-0.50%)
BAC : 29.94 (-0.63%)
HON : 166.46 (+0.15%)
JPM : 118.57 (-0.50%)
JNJ : 129.67 (+0.10%)
ORCL : 52.87 (-0.51%)
AMGN : 196.72 (+1.36%)
MSFT : 137.39 (+0.78%)
JCI : 43.86 (+0.34%)
MA : 276.25 (+0.79%)
LOW : 112.73 (+0.09%)
WFC : 48.76 (-0.45%)
INTC : 51.95 (-0.48%)
V : 176.45 (+0.19%)
SPGI : 256.12 (+2.65%)
BKNG : 2,077.44 (+0.22%)
BIIB : 238.70 (+1.09%)
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study

Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.

CELG : 98.60 (+0.22%)
JNJ : 129.67 (+0.10%)
NCNA : 7.61 (-9.24%)
AMGN : 196.72 (+1.36%)
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference

Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday, Sept. 18, 2019, in London. David W. Meline, executive vice...

AMGN : 196.72 (+1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Good.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 198.59
1st Resistance Point 197.65
Last Price 196.72
1st Support Level 194.91
2nd Support Level 193.11

See More

52-Week High 211.90
Last Price 196.72
Fibonacci 61.8% 194.48
Fibonacci 50% 189.10
Fibonacci 38.2% 183.72
52-Week Low 166.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar